Full-Time

Senior Validation Specialist-Computer System Validation

Confirmed live in the last 24 hours

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

10,001+ employees

Develops biopharmaceuticals for serious diseases

Compensation Overview

$82.6k - $134.8k/yr

Senior

Cambridge, MA, USA

Category
Public Health
Biology Lab & Research
Biology & Biotech
Requirements
  • BS/BA in Computer Science, Engineering, Chemistry, or Life Sciences
  • 5+ years of relevant work experience
  • Experience in a pharmaceutical or biopharmaceutical manufacturing facility
  • GMP experience is required
  • Experience with ERP, LIMS, QMS, and other GxP-regulated computerized systems and analytical instruments is required
Responsibilities
  • Planning and driving all CSV activities required to maintain quality compliance as per existing Policies and Procedures for RCM
  • Generating, carrying out, and reviewing master and completed qualification and validation protocols, summary reports and associated data for conformance to regulations, SOPs, specifications and other applicable acceptance criteria
  • Creating and maintaining validation documentation, including Validation Plans, Risk Assessments, Test Scripts and Reports
  • Identifying current and anticipated requirements for compliant computerized operations and suggests methods for the identification, implementation, and maintenance of the procedures, actions, and documentation to ensure compliance within the operation
  • Supporting regulator’s inspections and audits by providing validation documentation and explanations and communicates company’s computer validation policies
  • Generating, reviewing, editing, and approving change controls, impact assessments, SOPs, reports, as well as deviation notifications/investigations
  • Collaborating with IT, Automation, Quality Assurance and End Users to ensure system compliance as well as with outside contractors/vendors to complete validation tasks
  • Managing contingent workers as needed
Desired Qualifications
  • Excellent verbal and written communication skills
  • Continuously driving for improved processes for more efficient performance
  • Ability to work collaboratively as a part of a team
  • Flexibility with shifting priorities
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops medicines aimed at treating serious diseases such as cancer, eye diseases, and allergic conditions. The company uses its own technologies and extensive research to create new therapies, often working with academic institutions and other pharmaceutical companies to enhance its efforts. Regeneron generates revenue by selling its approved medicines and through partnerships that involve sharing the costs and profits of new treatments. Unlike many competitors, Regeneron focuses heavily on research and collaboration, which helps it stay updated with scientific advancements. The goal of Regeneron is to improve patient outcomes by providing effective treatments.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Greenburgh, New York

Founded

1988

Simplify Jobs

Simplify's Take

What believers are saying

  • Regeneron's acquisition of 23andMe enhances its consumer genomics capabilities.
  • Dupixent's success in phase 4 trials strengthens Regeneron's position in respiratory biologics.
  • Investment in Alnylam Pharmaceuticals indicates strategic interest in RNA interference technology.

What critics are saying

  • Regeneron's acquisition of 23andMe may face regulatory and privacy challenges.
  • Failure of AERIFY-2 study could impact investor confidence in COPD treatments.
  • Intensifying competition in biologics market pressures Regeneron to innovate continuously.

What makes Regeneron Pharmaceuticals unique

  • Regeneron excels in developing life-transforming medicines for serious diseases.
  • The company leverages proprietary technologies for innovative drug discovery.
  • Regeneron's strategic partnerships enhance its research and development capabilities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours

Company News

PharmiWeb
Jun 16th, 2025
Eaaci: Dupixent Demonstrated Superiority Over Xolair (Omalizumab) In Chronic Rhinosinusitis With Nasal Polyps In Patients With Coexisting Asthma In First-Ever Presented Phase 4 Head-To-Head Respiratory Study

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpointsDupixent also outperformed Xolair in improving such key signs and symptoms as nasal polyp size and sense of smell in CRSwNP, and lung function and disease control in asthma, with rapid improvements seen as early as 4 weeksResults reinforce the efficacy of Dupixent in treating both upper and lower respiratory diseases by targeting IL-4 and IL-13, two key drivers of type 2 inflammation Paris and Tarrytown, NY, June 15, 2025. Sanofi and Regeneron Pharmaceuticals, Inc. today presented positive results from the EVEREST phase 4 study of adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting asthma. In the study, Dupixent (dupilumab) outperformed Xolair (omalizumab) on all primary and secondary efficacy endpoints of CRSwNP, and in all asthma-related endpoints. The data are from the first-ever presented head-to-head respiratory study with biologic medicines and were shared today in a late-breaking oral presentation at the 2025 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress, Glasgow, UK. Eugenio De Corso, MD, PhD ENT Specialist, Otolaryngology, Head and Neck Surgery, Rhinology, A

PharmiWeb
Jun 2nd, 2025
Itepekimab Met The Primary Endpoint In One Of Two Copd Phase 3 Studies

Itepekimab met the primary endpoint in one of two COPD phase 3 studies. AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefit. AERIFY-2 study, a second Phase 3 study, did not meet the primary endpoint despite a benefit seen earlier in the study

MarketBeat
Jun 1st, 2025
Summit Global Investments Invests $849,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Regeneron Pharmaceuticals Inc. purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter worth approximately $1,045,822,000.

CNBC
May 27th, 2025
23Andme To Delist From Nasdaq, Deregister With Sec

A sign is posted in front of the 23andMe headquarters in Sunnyvale, California, on Feb. 1, 2024.Justin Sullivan | Getty Images23andMe on Tuesday announced it will voluntarily delist from the Nasdaq and de-register with the U.S. Securities and Exchange Commission, according to a release. The move comes after Regeneron Pharmaceuticals said earlier this month that it will acquire "substantially all" of 23andMe's assets for $256 million. The drugmaker came out on top following a bankruptcy auction for 23andMe, a once high-flying genetic testing company that filed for for Chapter 11 bankruptcy protection in March.This is breaking news. Please refresh for updates

Pharmaceutical Technology
May 20th, 2025
ATS 2025: Sanofi and Regeneron to launch new AIM4 trial for personalised asthma care

At the American Thoracic Society (ATS) 2025 Congress on 19 May, Sanofi and Regeneron announced the launch of a new Phase IIIb/IV clinical trial, AIM4, during an evening industry symposium.